Molecular Biology of Polycythemia and Thrombocytosis

Launched by UNIVERSITY OF UTAH · Jul 24, 2008

Keywords

ClinConnect Summary

**Clinical Trial Summary: Molecular Biology of Polycythemia and Thrombocytosis**

This clinical trial aims to better understand two blood conditions called Polycythemia and Thrombocytosis. These conditions involve having too many red blood cells (in Polycythemia) or too many platelets (in Thrombocytosis), which can lead to various health problems. The researchers are looking to identify specific genes and mutations that may be causing these disorders. By discovering the underlying genetic factors, the hope is to develop new treatments that can help manage or even cure these conditions.

If you are considering participating in this study, you may be eligible if you have a higher-than-normal hemoglobin level (more than 18 for men and more than 16 for women) or a high platelet count (more than 450,000). However, individuals with known causes for these conditions or certain heart and lung diseases will not be able to participate. Those who join the trial will help contribute to important research that could lead to better therapies in the future. Participants can expect to undergo tests to gather information about their blood and genetics, and they will be part of a team effort to advance medical knowledge in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects with an elevated hemoglobin concentration (\>18 in males and \>16 in females)
• • 2. Subjects with an elevated platelet count (\>450,000)
• Exclusion Criteria:
• • 1. Subjects who have a known acquired cause of polycythemia and thrombocytosis
• • 2. Subjects with heart disease, left to right heart shunt or severe pulmonary disease